Holen Sie sich die Stockscreener-App
18.04
0.22%
0.04
Handel nachbörslich:
18.04
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics: 2026 Catalysts Point To Further Upside (NASDAQ:DYN) - Seeking Alpha
FY2025 Earnings Forecast for DYN Issued By Lifesci Capital - MarketBeat
How Does Japan’s Orphan Nod Shape Dyne Therapeutics’ (DYN) Global Rare-Disease Strategy? - Yahoo Finance
(DYN) Risk Channels and Responsive Allocation - Stock Traders Daily
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - 富途资讯
CEO Change: What is Dyne Therapeutics Incs 5 year growth outlookQuarterly Portfolio Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Biotech Powerhouse with 134% Upside Potential - directorstalkinterviews.com
JPMorgan Chase & Co. Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $16.00 - MarketBeat
JP Morgan Updates Dyne Therapeutics (DYN) with a Neutral Rating - GuruFocus
Dyne Therapeutics (DYN) Gains Orphan Drug Status in Japan for DM - GuruFocus
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - Yahoo Finance
Campbell & CO Investment Adviser LLC Purchases Shares of 64,517 Dyne Therapeutics, Inc. $DYN - MarketBeat
Can Dyne Therapeutics Inc. scale operations efficientlyMarket Rally & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Why Dyne Therapeutics Stock Was Crushing it This Week - AOL.com
Jobs Data: Is Dyne Therapeutics Inc a turnaround storyWeekly Profit Report & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.9%Here's What Happened - MarketBeat
Is Dyne Therapeutics' (DYN) Late-Stage DMD Progress Redefining Its Rare Disease Investment Story? - simplywall.st
Analysts project 120% upside to Dyne Therapeutics, Inc. (DYN) - MSN
Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) - Insider Monkey
DYN: Transformative clinical data and commercial launches planned for 2026–2027 in DMD and DM1 - TradingView
DYN: Transformative DMD and DM1 therapies advance toward 2027 launches, backed by validated platform - TradingView
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Why Dyne Therapeutics Inc stock appeals to analystsEarnings Risk Report & Risk Managed Investment Signals - Bộ Nội Vụ
Fed Meeting: Why Dyne Therapeutics Inc stock attracts high net worth investorsLong Setup & Long-Term Safe Investment Plans - Bộ Nội Vụ
Aug Gainers: Why Dyne Therapeutics Inc stock is trending among retail tradersTrade Ideas & Real-Time Sentiment Analysis - moha.gov.vn
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - Investing News Network
Downgrade Watch: Can Dyne Therapeutics Inc weather a recessionTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors - Investing News Network
Day Trade: What is Dyne Therapeutics Incs 5 year growth outlookMarket Trend Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
(DYN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How risky is Dyne Therapeutics Inc. stock now2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
Why hedge funds are buying Dyne Therapeutics Inc. stockJuly 2025 Market Mood & Detailed Earnings Play Strategies - ulpravda.ru
$350 million fundraise shows potential of novel DMD therapy - The Pharma Letter
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6%Here's What Happened - MarketBeat
Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus - TechStock²
Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus - ts2.tech
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.7%What's Next? - MarketBeat
Liquidity Mapping Around (DYN) Price Events - Stock Traders Daily
Dyne Therapeutics (DYN) climbs 9.5% on stellar results for DMD therapy candidate - MSN
Dyne Therapeutics Earnings Notes - Trefis
Free cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Free cash flow per share of Dyne Therapeutics, Inc. – BOATS:DYN - TradingView — Track All Markets
CapEx per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
Operating cash flow per share of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView — Track All Markets
First Week of February 2026 Options Trading For Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat
DYN (Dyne Therapeutics) EV-to-OCF : -7.12 (As of Dec. 27, 2025) - GuruFocus
Why analysts see a huge upside for Dyne Therapeutics (DYN) - MSN
Dyne Therapeutics (DYN): Valuation Check After Board Addition Signals Next Phase of Commercial Growth - Sahm
Dyne Therapeutics appoints Vikram Karnani to board of directors By Investing.com - Investing.com Nigeria
Dyne Therapeutics Bets Big On Breakthrough Muscle Disease Treatments - Finimize
Dyne Therapeutics (DYN): Reaffirmed Buy Ratings Prompt Fresh Look at Valuation After Neuromuscular Data Update - Yahoo Finance
Dyne Therapeutics appoints Vikram Karnani to board of directors - Investing.com
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Deep Dive Into Its 87% Potential Upside - DirectorsTalk Interviews
Dyne Therapeutics Appoints Vikram Karnani to Board - TipRanks
Dyne Therapeutics appoints Vikram Karnani to board - MSN
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):